AXSM250117C87500
- 11.30
- -2.85-20.14%
Axsome Therapeutics Newsroom
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $124
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Axsome Therapeutics Analyst Ratings
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Positive Outlook for Axsome Therapeutics: Buy Rating Backed by Promising AXS-05 Prospects
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Axsome Therapeutics: Promising Growth Trajectory Justifies Buy Rating Amidst Auvelity's Commercial Success
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $175
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
Axsome Therapeutics (AXSM) Gets a Buy From RBC Capital
Axsome Therapeutics Analyst Ratings
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Axsome Therapeutics Analyst Ratings
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $121
Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $175